These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35771027)

  • 1. Insulin Pump-Associated Adverse Events in a Brazilian Reference Center for the Treatment of Diabetes Mellitus: Proposal for a Taxonomy of Device Failures in Adults, Adolescents, and Children.
    Neves ALD; Martins LEG; Gabbay MAL; Cavicchioli G; Tenorio FS; Cunha TS
    J Diabetes Sci Technol; 2024 Jan; 18(1):74-81. PubMed ID: 35771027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
    Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R
    Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin pump-associated adverse events in children and adolescents--a prospective study.
    Wheeler BJ; Heels K; Donaghue KC; Reith DM; Ambler GR
    Diabetes Technol Ther; 2014 Sep; 16(9):558-62. PubMed ID: 24796368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.
    Pickup JC; Yemane N; Brackenridge A; Pender S
    Diabetes Technol Ther; 2014 Mar; 16(3):145-9. PubMed ID: 24180294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
    Potti LG; Haines ST
    J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.
    Jeitler K; Horvath K; Berghold A; Gratzer TW; Neeser K; Pieber TR; Siebenhofer A
    Diabetologia; 2008 Jun; 51(6):941-51. PubMed ID: 18351320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type.
    Ross P; Gray AR; Milburn J; Kumarasamy IM; Wu F; Farrand S; Armishaw J; Wiltshire E; Rayns J; Tomlinson P; Wheeler BJ
    Acta Diabetol; 2016 Dec; 53(6):991-998. PubMed ID: 27585938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey.
    Abaci A; Atas A; Unuvar T; Demir K; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2009 Jun; 22(6):539-45. PubMed ID: 19694201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
    Colquitt JL; Green C; Sidhu MK; Hartwell D; Waugh N
    Health Technol Assess; 2004 Oct; 8(43):iii, 1-171. PubMed ID: 15488165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight in adolescents with type 1 diabetes mellitus during continuous subcutaneous insulin infusion (CSII) therapy.
    Raile K; Noelle V; Landgraf R; Schwarz HP
    J Pediatr Endocrinol Metab; 2002 May; 15(5):607-12. PubMed ID: 12014519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus.
    Alemzadeh R; Palma-Sisto P; Holzum M; Parton E; Kicher J
    Diabetes Technol Ther; 2007 Aug; 9(4):339-47. PubMed ID: 17705689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
    Giménez M; Elías I; Álvarez M; Quirós C; Conget I
    Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.
    Boland EA; Grey M; Oesterle A; Fredrickson L; Tamborlane WV
    Diabetes Care; 1999 Nov; 22(11):1779-84. PubMed ID: 10546007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study.
    Abell SK; Suen M; Pease A; Boyle JA; Soldatos G; Regan J; Wallace EM; Teede HJ
    Diabetes Technol Ther; 2017 May; 19(5):280-287. PubMed ID: 28282241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes mellitus: a systematic mapping review.
    Alvarenga CS; La Banca RO; Neris RR; de Cássia Sparapani V; Fuentealba-Torres M; Cartagena-Ramos D; Leal CL; Esper MV; Nascimento LC
    BMC Endocr Disord; 2022 Feb; 22(1):43. PubMed ID: 35183150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.